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ABSTRACT
Objective: To systematically review and appraise the
quality of economic evaluations assessing
centralisation of specialised healthcare services.
Methods: A systematic review to identify economic
evaluations on centralisation of any specialised
healthcare service. Full economic evaluations
comparing costs and consequences of centralisation of
any specialised healthcare service were eligible for
inclusion. Methodological characteristics of included
studies were appraised using checklists adapted from
recommended guidelines.
Results: A total of 64 full-text articles met the inclusion
criteria. Two studies were conducted in the UK. Most of
the studies used volume of activity as a proxy measure
of centralisation. The methods used to assess
centralisation were heterogeneous. Studies differed in
terms of study design used and aspect of centralisation
they considered. There were major limitations in
studies. Only 12 studies reported the study perspective.
Charges which are not true representation of costs were
used by 17 studies to assess cost outcomes. Only 10
reported the detailed breakdown of the cost
components used in their analysis. Discounting was
necessary in 14 studies but was reported only in 7
studies. Sensitivity analyses were included by less than
one-third of the studies. The applicability of the
identified studies to a setting other than the one they
were conducted in is questionable, given variations in
the organisation of services and healthcare costs.
Centralisation as a concept has also been variably and
narrowly defined as activity of specific services which
may not reflect the wider aspects of centralisation.
Conclusions: Confounded and biased information
coming from studies without standardised methods
may mislead decision-makers towards making wrong
decisions on centralisation. It is important to improve
the methodology and reporting of economic
evaluations in order to provide more robust and
transferable evidence. Wider aspects of healthcare
centralisation should be considered in the estimates of
costs and health outcomes.
BACKGROUND
Centralisation of specialised healthcare ser-
vices is typically characterised by reorganisa-
tion of healthcare services into fewer
specialised units serving a higher volume of
patients and aims to improve patient out-
comes and efﬁciency. Lord Darzi’s 2007
report1 recommended the reorganisation of
London stroke and major trauma services
into specialised centralised higher volume
units catering for large populations with
high-tech facilities and senior medical con-
tinuity. A number of studies2–9 suggest that
reconﬁguring healthcare services into fewer
consolidated units will lead to increase in
high-quality care and better patient out-
comes. Cost savings arguably resulting from
the economies of scale is also one of the
driving forces behind centralisation of
healthcare services.10 11 However, redistribu-
tion of limited resources could have second-
ary or unpredictable effects such as
increased costs of access for patient and
their carer. Increased journey distance to
hospital may reduce healthcare utilisation
particularly in some groups of population
such as the elderly, those with poor socio-
economic status and those with poor access
to transport.10 12–14 Increased journey dis-
tance may also lead to increased risk of mor-
tality in patients with life-threatening
medical emergencies, whereas in some
Strengths and limitations of this study
▪ This is the first systematic review to comprehen-
sively attempt to appraise the methodological
quality of economic evaluations assessing cen-
tralisation of specialised healthcare services irre-
spective of their speciality.
▪ Checklists adapted from recommended standard
guidelines were used to assess included studies.
▪ While rigorous searches were adopted, it is pos-
sible that some relevant publications may have
been missed.
▪ This review only examines the quality based on
the information reported, and judgement could
not be made on the quality of conduct from
what was reported by studies.
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cases, the beneﬁts of specialist care in centralised
healthcare services may outweigh the detriments of
increased travel times.15 Thus, it is important to under-
stand the trade-off between the quality of care and cost
of centralisation. Economic evaluation methods can be
used to explore this trade-off and inform decisions as
to whether the resources required or redistributed to
centralise services are ‘worth’ the health outcomes
achieved.
Economic evaluations compare the costs and conse-
quences of two or more competing healthcare inter-
ventions to identify which makes best use of limited
resources. On the basis of the consequences measured
and valued, the full economic evaluation techniques
are classiﬁed as cost-effectiveness analysis (CEA), cost-
consequence analysis (CCA), cost-beneﬁt analysis
(CBA) and cost-utility analysis (CUA) and can be
based on primary empirical studies such as trials, deci-
sion analytic modelling or a combination of the two
approaches.16
Economic evaluations are increasingly used in decision-
making,17–19 but the methodological rigour varies and
this can lead to erroneous conclusions being drawn.
Therefore, when considering the economic evidence on
centralisation of healthcare services, it is important to sys-
tematically identify relevant economic evidence and
appraise the methodological quality. Such a review has
not hitherto been published. The aim of this study
was to systematically review and critically appraise the
methodological quality of economic evaluations con-
sidering centralisation of specialised healthcare services.
METHODS
Search strategy
A comprehensive and systematic literature search in the
database of PubMed, National Health Service Economic
Evaluation Database (NHS EED), Health Economic
Evaluations Database (HEED) and Excerpta Medica
Database (EMBASE) was ﬁrst undertaken in January
2015 to identify studies on economic evaluation of cen-
tralisation of any healthcare services. The search was
updated on 10 March 2016 to check for any new publi-
cations. However, HEED and NHS EED ceased their
searches in December 2014, so 31 December 2014 is the
date of last search of HEED and NHS EED. In addition,
the reference lists of the retrieved articles from the
search were also manually searched for relevant publica-
tions. Google was also used to check for relevant articles.
The search was performed using an extensive search
strategy using keywords and free text for each of the
databases, with no restrictions on date and year of publi-
cation. A detailed search strategy is shown in box 1. The
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA)20 guidelines were closely fol-
lowed during this review.
Box 1 Search strategy used in the review
EMBASE
#1 ((Emergency adj (medici* OR service* OR department)) OR Trauma OR (Speciali* adj (health OR center OR care OR unit OR medical
OR service)) OR care OR health OR clinical OR Hospital OR Acute)
#2 (Centrali* OR Regionali* OR Reconfigurat* OR Reorgani* OR Redesign* OR Consolidat* OR Merg*)
#3 1 AND 2
#4 (cost OR cost adj (effective* OR utility* OR saving* OR minimi* OR analysis* OR benefi* OR illness*))
#5 3 AND 4
PubMed
#1 ((Emergency adj (medici* OR service* OR department) OR “ED” OR “A&E” OR Trauma OR (Speciali* adj (health OR center OR care
OR unit OR medical OR service)) OR care OR health OR “clinical service*” OR Hospital OR Acute))
#2 (Centrali* OR Regionali* OR Reconfigurat* OR Reorgani* OR Redesign* OR Consolidat* OR Merg* OR Volume)
#3 1 AND 2
#4 (cost OR cost adj (effective* OR utility* OR saving* OR minimi* OR analysis* OR benefi* OR illness*)
#5 3 AND 4
NHS EED
#1 (centralisation OR concentration OR volume OR specialization OR regionalization OR multidisciplinary OR reconfiguration OR
Reorganization)
#2 (“Emergency Medical Services” OR “Emergency Department” OR A&E OR Specialized OR Trauma OR “Acute Care” OR Hospital OR
“Healthcare” OR “Health Care Service” OR “Clinical Service” OR “Vascular Service” OR Cancer OR Stroke)
#3 Cost OR Economic OR Saving OR Outcome OR Impact OR Implication OR “health economic”
HEED
#1 Hospital OR “health care” OR “health care service” OR Emergency OR Trauma OR “Acute Care” OR “Vascular Service” OR Centre OR
Stroke OR Cancer
#2 Centrali* OR Region* OR Reconfigur* OR Consolidat* OR Merg* OR Concentrat* OR Reorgani* OR Redesign* OR “high volume”
#3 1 AND 2
#4 Cost OR Economic OR “health economic” OR Impact OR Implication OR Evaluation OR Outcome OR Effect OR Efficiency OR Sustain
#5 3 AND 4
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Selection criteria
Inclusion/exclusion criteria were used to select studies.
Studies were included in the review according to the fol-
lowing criteria:
1. Full economic evaluations comparing costs and con-
sequences of at least two alternatives were included,
that is, those using the following methodologies:
CCA, CEA, CUA or CBA. Partial economic evalua-
tions, that is, those not involving comparison
between alternatives or not relating costs to beneﬁts
or those studies which only considered costs analysis/
comparison/description were excluded.
2. All relevant health economic evaluations were conside-
red, including those alongside high-quality randomised
trials, modelling studies based on a meta-analysis of
data from high-quality randomised trials or using sec-
ondary data from literature and those based on obser-
vational studies or analysis of large administrative
databases.
3. Literature reviews and studies focusing only on meth-
odology were excluded. Reviews, letters, comments,
conference abstracts and other general articles which
limited the assessment of their methodological
quality were also excluded.
4. Only publications in the English language were
included.
5. An assessment of centralisation of any specialised
healthcare service was included; assessment of institu-
tional/hospital volume of activity as a proxy for cen-
tralisation was included but excluded those assessing
centralisation on the basis of surgeon/physician
volume which measure individual clinician impact
rather than the service. It was assumed that the out-
comes achieved by a surgeon/physician are mainly
driven by the resources provided at the institutional
level.
6. Only publications from peer-reviewed journals were
included; it is expected that studies published in
peer-reviewed journals have already undergone some
basic checks on their quality.
Data extraction
Data extraction from the full texts included in the
review was focused on key methodological features such
as study objective, population, type of economic evalu-
ation, overall design, economic perspective, time
horizon, comparator and intervention, incremental costs
and outcomes and handling of uncertainties. One
researcher (NB) independently carried out the extensive
search and extracted the information from the selected
studies, reviewed the evidence and wrote the manuscript
with all other authors (PM, CP and LV) who contributed
to the critical revision of the manuscript and provided
critical comments.
Quality assessment
Studies were assessed for their reporting quality using a
template (see online supplementary table S1) based on
the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS)21 and Drummond’s22
checklists. Scoring systems for quality ratings of included
studies were not used, but important aspects of eco-
nomic evaluations were summarised.
RESULTS
Literature search
The literature search of the databases initially generated
11 544 hits of potentially relevant articles. Screening of
titles and abstracts resulted in 86 articles which appeared
to meet the eligibility criteria. After a detailed review of
full text of these articles, 27 articles were excluded. The
reasons for exclusion of these full-text articles were: not
a full economic evaluation (12), only analysing surgeon
volume (8), not analysing centralisation aspects (5), not
an economic evaluation (1) and not a peer-reviewed
journal publication (1). References from identiﬁed
papers were also crosschecked and a further ﬁve full-text
articles were identiﬁed and included. A total of 64 full-
text articles met the inclusion criteria and were ﬁnally
considered in this review (ﬁgure 1). A list of studies
included in the review is available as online supplemen-
tary table S2.
Key characteristics of economic evaluations
An overview of the key characteristics of economic eva-
luations included in the review is presented in table 1.
It is recommended that studies provide a clear descrip-
tion of the location, setting and other relevant aspects of
the healthcare system so that external validity, generalis-
ability and transferability of study results in a different
setting can be assessed.21 All included studies have
clearly reported their location and setting. While the
majority of studies were undertaken in the USA (n=47),
two studies were carried out in the UK, one in Canada,
four in European countries and the rest (n=10) in Asian
countries. Most (n=51) used hospital volume (deﬁned
in terms of activity level) as a proxy for centralisation of
healthcare services; however, there was a wide variation
in the deﬁnition of high-volume and low-volume hospi-
tals across studies. The variation in deﬁnition of volume
may further complicate the impact of the ﬁndings gener-
ated from these studies. Volume alone cannot be a
proper measure of quality,23 and the improvement in
quality is rather explained by underlying mechanisms of
care such as staff expertise, resource availability and spe-
ciﬁc processes of care correlated with volume.24 25 The
theme of centralisation assessed was location of health
service in two studies, specialisation of healthcare ser-
vices in nine studies and multidisciplinary care in one
study.
It was observed that the majority of the studies fol-
lowed non-randomised designs, including retrospective
cohort (n=34) with one (13) also using cross-sectional
effectiveness data; cross-sectional (n=15) of which one
(9) was repeated cross-sectional; comparative case series
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(n=1); case control (n=2) of which one (33) was
matched case control; and before-and-after studies
(n=3). Cross-sectional designs are particularly prone to
selection and measurement bias. Uncontrolled
before-and-after study designs are generally considered
to have poor internal validity because they may fail to
account for any prevailing temporal trend which might
confound and bias the outcomes of the intervention.26 27
Only one study (10) which used a before-and-after study
design attempted to account for potential confounder
and bias by modelling intervention effects before and
after centralisation using several independent,
population-based datasets and by conducting sensitivity
analysis. However, this may be insufﬁcient because it has
been argued that controlled before-and-after studies
should have at least two intervention sites and two
control sites to control for site-speciﬁc confounding
effects on the observed differences between intervention
and control groups.28 Altogether, 11 studies used some
form of modelling approach as their analysis method.
Looking at the economic evaluation methods used in
the studies, most of the studies used CCA (n=50), where
costs and outcomes such as mortality, length of stay, com-
plications and readmissions were assessed in a disaggre-
gated form. CCA, a variant of CEA, presents a range of
outcomes of an intervention in a disaggregated form that
decision-makers are likely to use in a trade-off of their
importance; however, it can be challenging for decision-
makers to weigh up different outcomes against each
other and compare alternatives.16 CEA is an appropriate
economic evaluation method when the outcomes of alter-
natives can be expressed in common measures such as
cost per life years saved, costs per cases averted or costs
per readmissions avoided.16 CEA was used in only in four
studies. Seven studies (1, 2, 3, 26, 28, 45, 60) which were
reported as CEA were in fact CCA. CUA is considered the
Figure 1 PRISMA flow diagram of the study selection. PRISMA, Preferred Reporting Items for Systematic Reviews and
Meta-Analyses.
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best approach for decision-making in healthcare because
it allows broader comparisons to be made across widely
differing alternatives;16 29 nevertheless, it is limited to
measuring only health beneﬁts. The results of this review
showed that CUA method was used only in 10 studies.
CBA was not applied by any of the studies.
Studies assessed a wide range of healthcare services or
procedures such as stroke, cancers, trauma, accident and
emergency services, congestive heart failure, coronary
artery bypass grafting, pancreatitis, organ transplanta-
tions and other condition-speciﬁc surgical procedures. A
majority of studies (n=50) assessed elective care
Table 1 Summary of key characteristics of studies included in the review
Characteristics
Studies
(n) Study reference (see online supplementary table S2)
Study country
UK 2 10, 31
Germany 1 6
Netherlands 3 7, 11, 55,
Canada 1 13
USA 47 1, 2, 3, 4, 5, 8, 9, 12, 14, 17, 18, 19, 20, 22, 23, 24, 25, 26, 27, 28, 29, 30, 33,
34, 35, 36, 37, 38, 39, 40, 44, 45, 46, 48, 49, 50, 52, 53, 54, 56, 57, 58, 59, 60,
62, 63, 64
Taiwan 4 15, 32, 43, 51
Japan 4 16, 21, 42, 47
South Korea 2 41, 61
Aspect of centralisation
Hospital volume 51 1, 2, 3, 4, 6, 8, 9, 12, 15, 16, 17, 18, 19, 20, 21, 22, 24, 25, 26 ,27, 28, 29, 30,
32, 33, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
57, 58, 59, 60, 62, 63, 64
Hospital location 2 11, 31
Healthcare specialisation 10 5, 7, 10, 13, 14, 23, 34, 54, 55, 61
Multidisciplinary care 1 56
Study design
Decision analytic
modelling
11 4, 5, 6, 8, 10, 11, 12, 27, 54, 55, 60
Cohort 34 1, 2, 3, 7, 8, 13, 14, 15, 17, 18, 19, 23, 24, 25, 26, 29, 32, 35, 36, 39, 42, 43, 44,
47, 51, 52, 53, 56, 57, 58, 59, 62, 63, 64,
Case control 2 33, 45
Cross-sectional 15 9, 16, 20, 21, 22, 28, 30, 37, 38, 40, 41, 46, 48, 49, 50,
Before and after 3 10, 31, 61
Case series 1 34
Economic evaluation type
Cost utility analysis (CUA) 10 4, 5, 6, 10, 11, 13, 14, 27, 54, 55
Cost-effectiveness
analysis (CEA)
4 7, 8, 12, 56
Cost-consequence
analysis (CCA)
50 1, 2, 3, 9, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 57,
58, 59, 60, 61, 62, 63, 64
Economic perspective
Societal 4 7, 8, 12, 54
Societal and health
insurance
1 6
Healthcare 4 10, 13, 58, 63
Third-party payer 3 27, 56, 60
Not stated 52 1, 2, 3, 4, 5, 9, 11, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 28, 29, 30,
31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 55, 57, 59, 61, 62, 64
Targeted health services
Emergency 14 4, 5, 6, 10, 13, 14, 17, 30, 31, 32, 33, 34, 46, 61
Non-emergency 50 1, 2, 3, 7, 8, 9, 11, 12, 15, 16, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 35,
36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57,
58, 59, 60, 62, 63, 64
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Table 2 Quality assessment criteria for economic evaluations included in the review
Dimension of quality
Reported (study reference in online
supplementary table S2)
Not reported (study reference in online
supplementary table S2) Note
A clear description of the study objective and
comparators is provided
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
52 52: Not clearly stated
Characteristics of target population and
subgroups are described and analysed
1, 2, 3, 4, 6, 8, 9, 10, 11, 12, 13, 15, 16, 17,
18, 19, 20, 21, 23, 24, 25, 26, 27, 28, 29, 30,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64
5, 7, 14, 22, 31 55: Reference for target
population given; 22: only
stated no difference
between groups
Setting and location of the study is stated 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63,
64
Study perspective is clearly stated 6, 7, 8, 10, 12, 13, 27, 54, 56, 58, 60, 63 1, 2, 3, 4, 5, 9, 11, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 55, 57, 59, 61,
62, 64
7: Has only healthcare
payer costs; 12: not what
is stated; 60: not what is
stated
Time horizon of costs and benefits is clear 1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16,
17, 19, 20, 21, 22, 23, 26, 27, 28, 30, 31, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 44, 45, 46,
47, 49, 50, 51, 53, 54, 55, 56, 57, 58, 60, 61,
62, 63, 64
8, 18, 24, 25, 29, 32, 43, 48, 52, 59
Discount rate is stated or an explanation is
given if costs or benefits are not discounted
(where applicable)
4, 5, 6, 10, 12, 13, 14, 27, 54, 55 3, 7, 15, 51 5, 54, 13: Benefits only
Source and methods used to collect
effectiveness data described
1, 2, 3, 4, 5, 6, 7, 9, 10, 11, 12, 13, 14, 15, 16,
17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52,
53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64
8 8: Not clear
The primary outcome measure(s) for
economic evaluation are clearly stated
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39,
40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51,
52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62,
63, 64
Continued
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Table 2 Continued
Dimension of quality
Reported (study reference in online
supplementary table S2)
Not reported (study reference in online
supplementary table S2) Note
Quantities of resources are reported
separately from their unit costs
6, 7, 10, 11, 12, 54, 55, 54, 56, 1, 2, 3, 4, 5, 8, 9, 13, 14, 15, 16, 17, 18, 19,
20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 57, 58,
59, 60, 61, 62, 63, 64
7: Only unit costs
reported separately, 55
ref to web table given
Approaches used to estimate resource use
and cost are clear
1, 2, 3, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 15, 16,
17, 19, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31,
32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43,
44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55,
56, 57, 58, 59, 60, 61, 62, 63, 64
9, 18, 20, 21
Cost components clear 6, 7, 10, 11, 12, 14, 42, 54, 55, 56 1, 2, 3, 4, 5, 8, 9, 13, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32,
33, 34, 35, 36, 37, 38, 39, 40, 41, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 53, 57, 58, 59, 60,
61, 62, 63, 64
Currency/price year are explicitly stated 2, 4, 5, 6, 9, 10, 12, 14, 19, 20, 26, 27, 29, 32,
35, 37, 40, 41, 43, 45, 47, 50, 51, 53, 54, 55,
58, 61, 62, 63
1, 3, 7, 8, 11, 13, 15, 16, 17, 18, 21, 22, 23,
24, 25, 28, 30, 31, 34, 33, 36, 38, 39, 42, 44,
46, 48, 49, 52, 56, 57, 59, 60, 64
Analytic methods supporting the evaluation
including methods for dealing with skewed,
missing or censored data, extrapolation
methods, methods for pooling data,
approaches to validate or make adjustments
to a model, methods for handling population
heterogeneity and uncertainty described in
details
1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29,
30, 31, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42,
43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54,
55, 56, 57, 58, 59, 60, 61, 62, 63, 64
7, 13, 14
Incremental costs and outcomes reported
(if applicable, incremental cost-effectiveness
ratios reported)
2, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 26, 41,
48, 54, 55, 56
1, 3, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,
27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38,
39, 40, 41, 42, 43, 44, 45, 46, 47, 49, 50, 51,
52, 53, 57, 58, 59, 60, 61, 62, 63, 64
11: Only in graphs
Sensitivity analysis carried out 1, 4, 5, 6, 7, 8, 10, 11, 12, 13, 14, 27, 33, 42,
45, 54, 55, 57, 60
2, 3, 9, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24,
25, 26, 28, 29, 30, 31, 32, 34, 35, 36, 37, 38,
39, 40, 41, 43, 44, 46, 47, 48, 49, 50, 51, 52,
53, 56, 58, 59, 61, 62, 63, 64
Limitations clearly discussed 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,
16, 17, 18, 19, 20, 21, 23, 24, 25, 26, 27, 28,
29, 30, 31, 32, 33, 34, 35, 36, 38, 39, 40, 41,
42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53,
54, 55, 56, 57, 58, 59, 60, 61, 62, 63
22, 37 Not clearly reported in
22, 37
Generalisability of findings discussed 1, 2, 6, 10, 15, 16, 17, 19, 20, 21, 28, 30, 31,
32, 33, 34, 35, 42, 53, 54, 60, 61
3, 4, 5, 7, 8, 9, 11 ,12, 13, 14, 18, 22, 23, 24,
25, 26, 27, 29, 36, 37, 38, 39, 40, 43, 44, 45,
46, 47, 48, 49, 50, 51, 52, 55, 56, 57, 58, 59,
62, 63
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centralisation issues and the remaining (n=14) focused
around those appearing to be emergency healthcare
need.
Methodological quality of economic evaluations
The results of the methodological quality assessment are
presented in table 2 and reﬂect inconsistency across the
studies assessing centralisation of healthcare services.
Study objectives and comparators
Cost-effectiveness may vary by population characteristics,
and it is recommended that these studied should be
clearly reported.21 It was observed that most of the
studies clearly reported their objectives, comparators
and description of the target population characteristics,
but statement of objective in one study (52) and popula-
tion characteristics reported by two studies (55, 22) were
incomplete; one (55) referred to another study for the
characteristics and the other (22) only stated that there
was no difference between the two population groups
analysed. Five studies (5, 7, 14, 22, 28) did not provide
any description and analysis of the target population
characteristics.
Perspective of the study
Perspective is the viewpoint from which the costs and
outcomes are evaluated and should be clearly stated in
an economic evaluation.21 Only 12 studies clearly
reported the perspective of the analysis. Among these,
ﬁve (7, 54, 9, 12, 60) reported the use of societal per-
spective, one (6) reported societal perspective along
with statutory health insurance perspective, four (11, 13,
58, 63) reported using healthcare perspective and two
(27, 56) reported third-party payers’ perspective.
However, on a closer examination, it was clear that three
(7, 9, 12) and one (60) of those studies which reported
using a societal perspective actually followed a health-
care and payers’ perspective, respectively.
Effectiveness data
It was observed that the source and methods of effect-
iveness data were clearly reported in all studies but
one (9). The majority (n=52) of studies analysed the
data derived from a single-source database. One mod-
elling study (10) used information from three differ-
ent databases. Eight (4, 5, 6, 7, 11, 12, 54, 55)
modelling and two (13, 56) observational studies used
information from multiple sources including litera-
ture review and databases, but one (13) also carried
out a cross-sectional survey to derive effectiveness
data. A major limitation of eight (4, 5, 6, 7, 12, 54, 55,
13) of these studies which reported using effectiveness
estimates from literature review was the failure to
report whether a systematic review was conducted,
making it unclear whether the best available evidence
was used.
Outcomes assessed
The commonly used outcome measures in studies were
in-hospital mortality, length of stay in the hospital, read-
missions, life years gained or deaths averted, complica-
tions, length of stay in the intensive care unit (ICU),
long-term survival and quality-adjusted life years
(QALYs). Only 11 studies assessed QALYs as one of their
outcome measures. Three studies (21, 43, 61) assessed
length of stay in the hospital as the only outcome
measure (see online supplementary table S2).
Costing
The costs resulting from healthcare centralisation can
be broadly divided into direct and indirect costs. Direct
costs are healthcare-related costs that result from
inpatient or outpatient healthcare services used to
address the health problem—for example, costs of
surgery, drug treatment, laboratory tests, staff and equip-
ment. Indirect costs are other types of costs that occur
outside the healthcare sector—for example, value of
time loss such as productivity/wages lost or leisure time
lost, travel costs and costs associated with other aspects
such as childcare. Direct costs were included in all
studies included in this review (see online supplemen-
tary table S2). These were the hospital costs such as
costs of diagnosis, treatment and surgery associated with
the illness; however, 18 of the studies used hospital
charges and did not report any conversions to actual
incurred costs. Eight (1, 6, 10, 11, 12, 13, 14, 54) studies
appeared to have considered indirect costs in their ana-
lysis (see online supplementary table S1); however, in
one (11) of these, economic evaluation was restricted to
travel costs to hospitals borne by patients, two (1,13)
were not clear in what indirect costs were included, one
(54) included costs of lost productivity and one (6)
included costs of hospital infrastructure and informal
carer travel, but explicitly excluded the productivity costs
citing an average patient age of 74 years. All studies
mentioned how the resource use and costs were esti-
mated and all seem to have used activity-based costing
method, but three (18, 20, 21) were not clear enough.
Only 10 (6, 7, 10, 11, 12, 14, 42, 54, 55, 56) of the
studies reported the detailed breakdown of components
of the total costs assessed. Quantities of resource use
and unit costs were reported in eight studies (6, 7, 10,
11, 12, 54, 55, 56); however, in two (7, 56) of these
studies, only unit costs were presented and resource use
was not presented separately with one (56) only present-
ing fee codes.
Adjustments for timing of costs and benefits
It is recommended that the time horizon over which the
costs and consequences of an intervention occur and
any discount rate used should be stated.21 In this review,
it appeared that 40 studies had a time horizon of less
than a year. Discounting was not reported, nor is it
necessary in these studies with a time horizon shorter
than 1 year. However, it is recommended that analysts
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should report this as 0% discount rates for clarity.21
Fourteen studies (3, 4, 5, 6, 7, 11, 12, 13, 14, 15, 27, 51,
54, 55) had a time horizon longer than 1 year, but only
seven (4, 6, 11, 12, 14, 27, 55) reported discounting
costs and effects. In three studies (5, 13, 54), the time
horizon for costs and effects appeared to be different
and effectiveness data only was discounted. Costs in two
(13, 54) appeared to have incurred within a year and dis-
counting was not necessary. In the other study (5), the
costs were expected for 10 years, but discounting was still
not reported. Justiﬁcation on why costs were not dis-
counted was not provided. It was difﬁcult to ascertain
the time horizon in 10 studies (9, 18, 24, 25, 29, 32, 43,
44, 52, 59).
Price changes over time and research settings.
Reporting dates, currency and any conversions facilitate
comparisons of results from studies carried out at differ-
ent times and jurisdictions. It is recommended that
price year, the currency used and any currency conver-
sions are reported.21 Currency or price dates and con-
versions were explicitly stated by only 30 studies.
Statistical analysis
All the analytic methods used in the studies must be
reported to allow judgement of the appropriateness of
the methods and the corresponding results in economic
evaluations.21 Single study-based economic evaluations
should report regression methods that are used in their
analysis.21 The majority of studies (n=53) in this review
were primarily single study-based economic evaluations
and among these only 45 studies explicitly reported the
regression methods and other statistical tests used in
their analysis. Reporting of statistical analysis in ﬁve
studies (31, 39, 46, 52, 56) was very limited. Among
these, one (46) only stated using logistic regression ana-
lyses for demographic and clinical variables, but nothing
was reported on costs. Three studies (31, 52, 56)
reported the test of statistical signiﬁcance in the differ-
ence. One (39) of these studies reported the tests of sig-
niﬁcance but also indicated accounting for clustering
effects in groups, one (52) only stated using non-
parametric analyses in testing continuous variables but
failed to explain further, while another one (56) only
stated that comparisons between groups were made by
analysis of variance (ANOVA) and did not provide
further details. Three studies (7, 13, 14) did not report
any statistical methods in analyses of data. Altogether, 24
single empirical studies reported using statistical
methods to account for skewed distribution of costs and
resource utilisation data, and 14 of them also indicated
accounting for potential clustering effects in the groups
studied.
Model-based economic evaluations should describe
and report methods used in estimating parameters used
in the model.21 Among the 11 model-based economic
evaluations in this review, seven studies (4, 6, 10, 11, 27,
54, 55) clearly reported the model parameter estimation
methods; however, in four (27, 54, 55, 60) of these
studies, there was no indication that any possible hetero-
geneity effects in parameters were addressed. Three
studies (5, 8, 12) reported parameter estimation
methods poorly, and reported limited explanation on
estimation of transition probabilities; however, one (12)
study indicated that heterogeneity was addressed.
Ignoring heterogeneity effects in parameters may inﬂu-
ence the results of an economic evaluation.30 Only two
(6, 12) reported half-cycle corrections to account for
transition events occurring halfway through the cycle.
Not incorporating half-cycle corrections in states may
lead to overestimation or underestimation of economic
evaluation outcomes.31 Several methods for analysing
healthcare costs and handling patient heterogeneity are
currently in practice.30 32 33 Appropriateness of these
methods is dependent on the data used by each study,
but it is beyond the scope of this review.
Consideration of uncertainty
Effects of uncertainties in parameters arising out of
methodological assumptions, sampling variation or struc-
ture of analyses should be described in economic evalua-
tions.21 It was observed that analyses in 54 studies were
mainly based on patient-level data; however, only 15
studies presented CIs for cost and effect results and one
presented cost-effectiveness acceptability curves. Some
form of sensitivity analysis was included by less than
one-third of the studies (n=19). Among the eight studies
(1, 7, 13, 14, 33, 42, 45, 57) which were mainly analysis
of patient-level data, only seven (1, 7, 13, 14, 33, 42, 57)
performed sensitivity analysis: six used one-way sensitivity
analysis and one (13) used two-way sensitivity analysis.
Eleven studies (4, 5, 6, 8, 10, 11, 12, 27, 54, 55, 60)
were model-based analysis. Six (4, 5, 8, 11, 27, 60) per-
formed one-way sensitivity analysis, although reporting
was limited to threshold graphs in one (27). In another
ﬁve (6, 10, 12, 54, 55), one-way or two-way sensitivity ana-
lysis was required along with probabilistic sensitivity
analysis.
Presentation of results
The recommended practice in economic evaluation
studies is to report mean values for the main categories
of estimated costs and outcomes of interest as well as the
mean differences between the comparator groups and—
if applicable—incremental cost-effectiveness ratios
(ICERs).21 Although all of the studies in this review pre-
sented mean values for the estimated costs and major out-
comes, it was observed that only 18 studies reported
results in terms of incremental costs and outcomes or
ICERs. One (11) of these only presented the results
graphically, and the economic evaluation results were not
reported clearly in numerical terms. Study limitations
were clearly discussed by all studies but two (32, 37).
Generalisability of study ﬁndings was discussed only by 22
studies.
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DISCUSSION
The main purpose of this review was to critically appraise
the methodological quality of published economic evalu-
ation considering centralisation of specialised healthcare
services. The review identiﬁed 64 studies undertaking
some form of economic evaluations of the centralisation
of healthcare services. Considerable variation was
observed in the methodological approaches used. The
studies reviewed generally did not adhere to current
standards for reporting economic evaluations, and while
they might have been sufﬁcient for the purpose they
were originally conducted, they provide a very limited
evidence base to guide decision-makers in other
settings.
Most of the studies in this review used non-
experimental designs. It may be impossible or impracti-
cal to undertake randomised trials to assess centralisa-
tion; therefore, quasi-experimental designs such as
controlled before-and-after studies, interrupted time
series and repeated-measures studies may generate more
robust and convincing evidence compared with non-
experimental designs.26 Modelling is also useful when
there is a need to understand the long-term costs and
effects of an intervention; however, validity of the model-
ling results depends on the evidence and assumptions
on which they are based.16
The health outcomes assessed in studies were generally
appropriate to their objectives. However, QALY, which is
widely preferred as a summary measure of quantity and
quality of life outcomes in health economics,34 was
assessed in only 11 studies. Length of stay is widely used
as quality and efﬁciency measures of healthcare services.
It is signiﬁcantly inﬂuenced by several other factors, and
it has been argued that length of stay alone should not be
used as a quality measure to compare healthcare services
unless appropriately adjusted.35 Nevertheless, length of
stay was the only health outcome measure assessed in
three studies (21, 43, 61) in this review. Most of the
studies had short-term follow-up, and it is possible that
their outcomes would have been different if they had
considered longer time frame.
It is important to clearly state the perspective of analysis
in studies because cost-effectiveness may vary with the
perspective and an intervention which is cost-effective
from one viewpoint and may not be from another. For
example, from the National Health Service (healthcare)
perspective which typically includes direct medical costs,
centralisation of hospitals may appear cost-effective, while
from a societal perspective which includes broader costs
to the society, such as lost productivity and leisure time
costs due to additional travel time, costs to family
members or caregivers, centralisation may not appear
cost-effective. Nevertheless, a large majority (n=52) of
studies fail to state their analysis perspective. Studies
always did not consider all costs relevant to a particular
perspective. One study(6) in this review followed a soci-
etal perspective but did not consider the lost productivity
costs in the elderly citing their age; however, leisure time
forgone may not be valueless to the elderly and not con-
sidering it may discriminate against healthcare interven-
tions aimed towards the elderly population. Furthermore,
it is also important that the source and methodology
used in generating effectiveness are well reported
because validity of the estimate of the measure of effect-
iveness used in the studies depends on the methodology
used to generate those estimates.
A number of studies in this review have used hospital
charges as costs. However, hospital charges are not con-
sidered a good approximation of costs because charges
are essentially the list prices which are set to compensate
costs such as free or discounted care to the poor, facility
costs and other community service costs incurred by any
healthcare organisation.36 In this context, it is possible
that the charges set by a centralised or a high-volume
hospital for a particular treatment are higher than that
of a low-volume local hospital to compensate for the
better facilities and services it provides to its patients.
Alternatively, high-volume central hospitals may charge
less than small-volume local hospitals by spreading out
their costs of facilities and equipment over a very large
volume of patients they cater to. Therefore, using
charges in place of costs to determine if centralisation
reduces healthcare costs could lead to unsubstantiated
conclusions on healthcare centralisation.
Transparency in the costing methodology and cost
components is another important aspect in economic
evaluations. Depending on the purpose and the context,
there exists variation in estimates of commonly used
costing approaches;37 therefore, unclear reporting of
estimation of resource use and costs may make it hard to
judge applicability of estimates in a different healthcare
setting. It is recommended that costing approaches and
data sources are clearly described in economic evalua-
tions.21 Limited data may lead to biased conclusions, but
incomplete reporting may make it hard to judge applic-
ability of study results for a different setting.
Nevertheless, very few studies (n=10) in this review have
presented the cost components clearly.
Centralisation would also be expected to impact on
the travel distance to hospitals, resulting in changes in
cost to health services and patients as well as potentially
health outcomes. The impact on ﬁnancial and other
costs of accessing healthcare caused by centralisation
may have equity implications as increases in cost may be
disproportionately felt by those less well-off who coinci-
dently may also be in the greatest need.38 Furthermore,
costs generated by the increased distance to hospitals
would become a signiﬁcant component of the total costs
of centralisation. Thus, it is important that wider aspects
of healthcare centralisation are considered in the esti-
mates of costs and health outcomes.
Notwithstanding the limitations as presented earlier,
economic evaluations assessing QALYs as well as other
relevant health outcomes and direct and indirect costs
would give a better picture of costs and beneﬁts of
healthcare centralisation (see online supplementary
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table S1). Sensitivity analysis helps to understand the
robustness of their ﬁndings by varying the assumptions
in the values of major variables.
Many health services are facing an increasing pressure
to centralise healthcare services into fewer but more spe-
cialised units. The case for greater concentration of
some of the specialised health services reﬂects a rela-
tionship between quality of care and patient volume,
derived from the greater clinical expertise, more specia-
lised facilities and greater standards of care in the con-
centrated services.39 While it may be attractive and fairly
acceptable to transfer ﬁndings from one setting to
another, healthcare costs and outcomes often have
limited transferability across settings because of differ-
ences in health and economic systems.40 In the light of
the methodological limitations and differences, decision-
makers should take caution while making decisions on
the basis of existing economic evaluation studies on cen-
tralisation of healthcare services. Decisions on centralis-
ing any healthcare speciality should be informed by
ﬁndings from methodologically strong economic evalu-
ation studies considering multifaceted aspects of central-
isation. Studies adhering to standard guidelines on
economic evaluations and with a clearly reported metho-
dology in terms of cost components, outcomes, analysis
perspective, time horizon, robustness of the ﬁndings,
limitations and generalisability aspects of the ﬁndings
would assist decision-making.
Strengths and limitations
A number of economic evaluations on centralisation of
specialised healthcare services have been conducted;
however, studies assessing the methodological quality of
these economic evaluations are lacking. An earlier
review41 of economic evaluations considering centralisa-
tion was narrower and focused only on speciﬁc health
issues such as cancer. To the best of our knowledge, this
is the ﬁrst systematic review to comprehensively attempt
to assess the methodological quality of economic evalua-
tions assessing centralisation of specialised healthcare
services irrespective of their speciality. One of the
strengths of this review is the use of a checklist adapted
from recommended standard guidelines. While we have
adopted rigorous searches, we caution that we may have
left out some key search terms, and it is possible that we
may have missed some relevant English language publi-
cations. Databases may be sensitive to different search
terms, and use of generally similar search terms across
databases could have missed key papers. A more substan-
tive limitation is the exclusion of unpublished evalu-
ation, grey literature and non-English language studies.
However, it is also likely that unpublished and grey litera-
ture may either be of lower methodological quality or be
no different compared with the published studies.42
Since quality assessment was primarily conducted by
only one researcher, the likelihood of bias in quality
assessment cannot be ignored. Length of stay, also a sur-
rogate for cost, was assessed as a quality outcome
measure in this review, and because of this, some of the
studies were classiﬁed as CCA. Finally, though the check-
list used to assess the methodological quality was
adapted from standard guidelines, it only examines the
quality reported by studies. It was not possible to judge
the quality of conduct from what was reported by studies
and was beyond the scope of this study. Although argu-
ably, complete reporting is a part of good conduct and
the safe inference from incomplete reporting is to
assume the quality of conduct was poor.
CONCLUSION
This paper demonstrates economic evaluations on cen-
tralisation of specialised healthcare services have limited
methodological quality and their results should be inter-
preted with caution in other settings. The rationale
behind centralisation of specialised healthcare services is
the improvement in healthcare quality and its efﬁciency.
However, evidence coming from methodologically poor
studies may force decision-makers to make uninformed
decisions on centralisation. It is important to improve
the methodology and reporting of economic evaluations
so that decisions to centralise specialised healthcare ser-
vices are informed by robust evidence of improvements
in healthcare quality and efﬁciency arising out of cen-
tralisation. Future economic evaluations of specialised
healthcare centralisation should adhere to standard
guidelines on economic evaluations. Estimates of costs
and health outcomes of specialised healthcare central-
isation should consider wider aspects of centralisation.
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